Patent gridlock threatens India’s GLP-1 breakout

3 November 2025

Despite surging demand for affordable GLP-1 treatments, India’s path to generic semaglutide is far from smooth.

Even as IN 275964, the composition patent for (Wegovy) semaglutide was set to expire in September 2024, domestic players like Dr Reddy’s Laboratories (BOM: 500124) and Natco Pharma had accelerated development, aiming to undercut Novo Nordisk’s (NOV: N) $191 - $281 per month Wegovy pricing with sub-$6 generics.

Danish innovator took them to court

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



More ones to watch >




Today's issue

Company Spotlight



More Features in Generics